ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

A Comparative Intention-to-Treat Analysis of Liver Transplantation for HCC – Living Donor Liver Transplant vs. Deceased Donor Liver Transplant.

K. Tomiyama, N. Goldaracena, A. Barbas, M. Dib, G. Levy, L. Lilly, A. Ghanekar, I. McGilvray, E. Renner, M. Bhat, M. Selzner, M. Cattral, N. Selzner, P. Greig, D. Grant, G. Sapisochin.

Multi-Organ Transplant Program, University of Toronto, Toronto, ON, Canada.

Meeting: 2016 American Transplant Congress

Abstract number: A180

Keywords: Hepatocellular carcinoma, Liver transplantation, Living-related liver donors, Outcome

Session Information

Date: Saturday, June 11, 2016

Session Name: Poster Session A: Liver - Hepatocellular Carcinoma and Cholangiocarcinoma Malignancies

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Halls C&D

Related Abstracts
  • Listing for Liver Transplantation of Patients With Hepatocellular Carcinoma Using the Extended Toronto Criteria; an Intention-to-Treat Analysis
  • Outcomes of Living and Deceased Donor Liver Transplant Recipients According to the MELD Score

Introduction

Living donor liver transplantation (LDLT) can reduce waiting times and potentially decrease drop-out rates for cirrhotic patients with HCC. However, it has also been reported to be associated with higher recurrence rate. To elucidate the true benefit of LDLT, we conducted an intention-to-treat (ITT) analysis comparing LDLT to deceased donor liver transplantation (DDLT).

Material & Methods

All patients included in the waiting list with an HCC were included in the study. Patients with tumors found incidentally at explant were excluded. Patients with a potential living donor (donor was ABO compatible and a positive health questionnaire) were included in the LDLT group. Patients without a potential LD were included in the DDLT arm. Patient survival was calculated from the time of listing and from the time of LT. The median follow-up from the time of listing was 48.4 (19.4-95.3) months.

Results

Between January 2000 and December 2014, 664 adult patients with HCC were listed for LT at our center. Of these 119 (17.9%) were included in the LDLT group and 545 (82.1%) in the DDLT group. At listing, the tumor characteristics were similar between groups; ~40% of the cases were outside Milan criteria in both groups. The median time in the waiting list was 8.8 (IQR 6.3-15) in the LDLT compared to 15.5 (IQR 7-29.7) in the DDLT group, p<0.001. The drop-out rate was 10.9% in the LDLT group vs. 20.4% in the DDLT group, p=0.02. The cause of drop-out was tumor progression in most cases; 100% in the LDLT group vs. 82% in the DDLT group. Finally, 106 patients were transplanted with a LD and 434 with a deceased donor graft. The 1-, 3- and 5-years actuarial survival on an ITT basis was 86%, 74%, 68% in the LDLT group vs. 84%, 67%, 59% in the DDLT group, p=0.07. The recurrence rate was similar between groups (16% LDLT group vs. 18.9% DDLT group, p=0.6). The 1-, 3- and 5-years actuarial survival after LT was 94%, 81%, 70% LDLT group vs. 91%, 79%, 75% DDLT group, p=0.5.

Conclusion

LDLT for HCC has comparable post-transplant outcomes to DDLT with a lower drop-out rate. A shorter waiting time in this population does not seem to impact in post-transplant outcomes.

CITATION INFORMATION: Tomiyama K, Goldaracena N, Barbas A, Dib M, Levy G, Lilly L, Ghanekar A, McGilvray I, Renner E, Bhat M, Selzner M, Cattral M, Selzner N, Greig P, Grant D, Sapisochin G. A Comparative Intention-to-Treat Analysis of Liver Transplantation for HCC – Living Donor Liver Transplant vs. Deceased Donor Liver Transplant. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Tomiyama K, Goldaracena N, Barbas A, Dib M, Levy G, Lilly L, Ghanekar A, McGilvray I, Renner E, Bhat M, Selzner M, Cattral M, Selzner N, Greig P, Grant D, Sapisochin G. A Comparative Intention-to-Treat Analysis of Liver Transplantation for HCC – Living Donor Liver Transplant vs. Deceased Donor Liver Transplant. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/a-comparative-intention-to-treat-analysis-of-liver-transplantation-for-hcc-living-donor-liver-transplant-vs-deceased-donor-liver-transplant/. Accessed February 27, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Penis Transplantation: First U.S. Experience.
      • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
      • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
      • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
      • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

      Visit Our Partner Sites

      American Transplant Congress (ATC)

      Visit the official site for the American Transplant Congress »

      American Journal of Transplantation

      The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

      American Society of Transplantation (AST)

      An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

      American Society of Transplant Surgeons (ASTS)

      The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

      Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

      Privacy Policy

      loading Cancel
      Post was not sent - check your email addresses!
      Email check failed, please try again
      Sorry, your blog cannot share posts by email.
      This site uses cookies: Find out more.